Telomir Pharmaceuticals financials
$1.17−2.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$10.5M | -$12.2M |
| Net income | -$10.4M | -$16.5M |
| Net margin | — | — |
| Diluted EPS | $-0.33 | $-0.56 |
| EBITDA | -$10.5M | -$12.2M |
| Operating cash flow | -$3.7M | -$5.1M |
| Free cash flow | -$3.7M | -$5.1M |
| Diluted shares | 31.7M | 29.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $7.3M | $1.3M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $7.3M | $1.3M |
| Total liabilities | $1.4M | $681.0K |
| Shareholders' equity | $5.9M | $643.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology